Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valproate and Quetiapine for Agitated Delirium in Severe COVID-19 Pneumonia
NCT04513314Phase 4
Key facts
- Status
- Withdrawn
- Start
- Mar 2023
- Primary completion
- Mar 2023
- Sponsor
- University of Miami
- Modality
- Small Molecules
- Drugs
- valproic acid
- Conditions
- delirium
01
Overview
Phase 4, randomised, single-blind trial of valproic acid in delirium (2 arms), sponsored by University of Miami. Primary endpoint: Richmond Agitation-Sedation Scale at Day 7. Planned start Mar 2023; status: withdrawn.
02
Design
2 arms- Study design
- RandomizedSingle-blind
Standard of Care Only Group
Standard of Care (Dexmedetomidine, Midazolam, Ketamine, Propofol)
Treatment Arm Group
Valproate + Standard of Care (+ Quetiapine if needed)
03
Endpoints
Primary
Richmond Agitation-Sedation Scale
Secondary
Total Dose of Dexmedetomidine Administered
Incidence of Treatment Emergent Adverse Events
Beyond the preview
Go deeper on NCT04513314.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04513314.